A Randomized Phase 2 Study Evaluating the Safety, Pharmacokinetics and Efficacy of Venetoclax in Combination with Azacitidine Compared with Azacitidine Alone in Subjects with Treatment-Naive Higher-Risk Myelodysplastic Syndromes (MDS)
A study for patients with Myelodysplastic Syndromes (MDS) using study drug Venetoclax
Sponsor: AbbVie
Enrolling: Male and Female Patients
IRB Number: AAAR1077
U.S. Govt. ID: NCT02942290
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to evaluate the safety, pharmacokinetics (how much the study drugs are absorbed in your body at different times), and efficacy (how well the study drugs work) of venetoclax in combination with azacitidine compared to azacitidine alone in subjects with previously untreated higher-risk MDS.
This study is closed
Joseph Jurcic, MD
Do You Qualify?
Have you been diagnosed with MDS? Yes No
Are you at least 18 years of age? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator